Physician profile
Amy Thayer
NPI 1992161210
$3,729.17
in general payments reported to CMS, 2019-2025
23 companies · $934 in 2025
The $934 reported for 2025 was more than what 84% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $460 · 2022: $524 · 2023: $762 · 2024: $1,049 · 2025: $934.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,545 · Education: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,545.33 |
| Education | $199.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $779.81 | 2021-2025 | |
| Janssen Biotech, INC. | $496.35 | 2021-2025 | Tremfya |
| Novartis Pharmaceuticals Corporation | $370.47 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $282.12 | 2021-2025 | Ilumya, Winlevi |
| E.R. Squibb & Sons, L.L.C. | $254.93 | 2022-2025 | Sotyktu |
| Lilly USA, LLC | $196.05 | 2021-2025 | Taltz, Ebglyss, Zepbound |
| Almirall LLC | $190.33 | 2022-2025 | Klisyri, Seysara |
| Ucb, INC. | $189.28 | 2021-2025 | Bimzelx |
| Organogenesis INC. | $161.96 | 2021-2024 | Cygnus Dual |
| Dermavant Sciences, INC. | $124.36 | 2023-2024 | Vtama |
| Biofrontera INC. | $96.95 | 2022-2025 | Xepi, Bf-Rhodoled, Ameluz |
| Galderma Laboratories, L.P. | $84.93 | 2022-2025 | Aklief, Epsolay, Oracea |
| Boehringer Ingelheim Pharmaceuticals, INC. | $79.45 | 2023-2024 | Spevigo |
| Incyte Corporation | $79.29 | 2021-2023 | Opzelura |
| Amgen INC. | $75.72 | 2023-2024 | Otezla |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $68.12 | 2021-2024 | |
| Arcutis Biotherapeutics, INC. | $54.48 | 2024-2025 | Zoryve |
| Regeneron Healthcare Solutions, INC. | $47.91 | 2021-2025 | Libtayo |
| Kerecis Limited | $27.72 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Mallinckrodt Hospital Products INC. | $21.77 | 2025 | Acthar |
| Organon LLC | $16.92 | 2025 | Vtama |
| Genzyme Corporation | $16.19 | 2021 | |
| Leo Pharma INC. | $14.06 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Thayer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.